Stock 301331 ENWEI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Enwei Pharmaceutical Co., Ltd.

Equities

301331

CNE100005LC7

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-06 EDT 		5-day change 1st Jan Change
27.28 CNY +1.83% Intraday chart for Enwei Pharmaceutical Co., Ltd. +1.75% -2.74%
05-14 Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI
04-21 Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 2,789 2,911
Enterprise Value (EV) 1 2,211 2,520
P/E ratio 33.4 x 33.7 x
Yield 4.02% 1.93%
Capitalization / Revenue 4.03 x 3.71 x
EV / Revenue 3.2 x 3.21 x
EV / EBITDA 22.9 x 22 x
EV / FCF 53.6 x -36.6 x
FCF Yield 1.87% -2.73%
Price to Book 2.42 x 2.61 x
Nbr of stocks (in thousands) 103,805 103,805
Reference price 2 26.86 28.05
Announcement Date 4/21/23 4/21/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 592.5 620.7 634.2 679.7 691.6 785.2
EBITDA 1 122.7 129.4 136.5 129.5 96.47 114.8
EBIT 1 88.07 96.17 103.8 99.69 68.31 80.38
Operating Margin 14.86% 15.49% 16.36% 14.67% 9.88% 10.24%
Earnings before Tax (EBT) 1 115.1 109.8 124.5 119.1 81.86 101.3
Net income 1 86.25 82.59 98.74 101.7 67.8 86.31
Net margin 14.56% 13.31% 15.57% 14.97% 9.8% 10.99%
EPS 2 1.135 1.061 1.351 1.307 0.8039 0.8321
Free Cash Flow 1 -34.34 96.78 11.86 21.08 41.25 -68.83
FCF margin -5.8% 15.59% 1.87% 3.1% 5.97% -8.77%
FCF Conversion (EBITDA) - 74.78% 8.68% 16.28% 42.76% -
FCF Conversion (Net income) - 117.18% 12.01% 20.72% 60.85% -
Dividend per Share 2 0.7966 0.3854 0.5909 - 1.081 0.5405
Announcement Date 9/30/20 9/30/20 5/19/21 9/1/22 4/21/23 4/21/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 21.3 51.8 77.4 78.7 578 392
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -34.3 96.8 11.9 21.1 41.3 -68.8
ROE (net income / shareholders' equity) 24.7% 18.9% 19.6% 16.6% 7.55% 7.65%
ROA (Net income/ Total Assets) 7.22% 7.86% 8.12% 7.25% 3.75% 3.66%
Assets 1 1,195 1,051 1,216 1,403 1,807 2,357
Book Value Per Share 2 5.460 5.200 7.530 8.250 11.10 10.70
Cash Flow per Share 2 0.7000 0.6100 0.8100 0.8300 3.290 2.300
Capex 1 17 21.2 31.2 38.2 23.6 134
Capex / Sales 2.87% 3.42% 4.91% 5.62% 3.41% 17.07%
Announcement Date 9/30/20 9/30/20 5/19/21 9/1/22 4/21/23 4/21/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ENWEI PHARMACEUTICAL CO., LTD. Stock Enwei Pharmaceutical Co., Ltd.
-2.74% 377M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
NOVARTIS AG Stock Novartis AG
+11.88% 216B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301331 Stock
  4. Financials Enwei Pharmaceutical Co., Ltd.